



- (51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 31/16* (2006.01)
- (21) International Application Number:
PCT/US2013/036522
- (22) International Filing Date:
15 April 2013 (15.04.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/624,519 16 April 2012 (16.04.2012) US
61/759,469 1 February 2013 (01.02.2013) US
- (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).
- (72) Inventor: PURCELL NGAMBO, Lisa, A.; 88 Captain Shankey Drive, Garnerville, NY 10923 (US).
- (74) Agents: BOZICEVIC, Karl et al.; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, CA 94303 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: METHODS FOR TREATING OR PREVENTING INFLUENZA VIRUS INFECTION BY ADMINISTERING A SERINE PROTEASE INHIBITOR




FIGURE 5

(57) Abstract: The present invention provides methods for treating or preventing influenza virus infection. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising a type II transmembrane serine protease (TTSP) inhibitor. The TTSP inhibitor preferably functions by inhibiting the proteolytic cleavage of influenza hemagglutinin (HA0) into the functional subunits HA1 and HA2. In certain embodiments, the TTSP inhibitor is an inhibitor of transmembrane protease serine S1 member 2 (TMPRSS2), such as an anti-TMPRSS2 antibody or antigen-binding fragment thereof.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, **Published:**

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*

GW, ML, MR, NE, SN, TD, TG).